Showing 511-520 of 615 results for "".
A Review of Complications of Biologic Therapy for Psoriasis
https://practicaldermatology.com/topics/general-topics/1109_02-php/22053/Therapeutic success requires clinicians to understand emerging and established safety concerns.The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions.&nbs
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants
- James R. Headley Joins ELEVAI LABS as Strategic Advisorhttps://practicaldermatology.com/news/james-r-headley-joins-elevai-labs-as-strategic-advisor-a-strategic-advisor/2461450/Cosmetic industry veteran James R. Headley is joining
- Dr. Seemal R. Desai Elected to AAD Leadershiphttps://practicaldermatology.com/news/dr-seemal-r-desai-elected-to-aad-leadership/2461161/Seemal R. Desai, MD, FAAD, has been elected to serve as president of the American Academy of Dermatology (AAD) for one year beginning in March 2024. He will be installed as president-elect in March 2023. As president, Dr. Desai will lead the wor
- Michael R. Stewart Named Next President and CEO of MELA Scienceshttps://practicaldermatology.com/news/20141119-micheal_r_stewart_named_next_president_and_ceo_of_mela_sciences/2459057/MELA Sciences, Inc. developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, announced that its Board of Directors has named Michael R. Stewart, 57, as the company's n
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
- Alma Lasers Releases Soprano ICE Multi-Platform Hair Removal System with Alex™ Technologyhttps://practicaldermatology.com/news/alma-lasers-releases-soprano-ice-multi-platform-hair-removal-system-with-alex-technology/2458984/Alma Lasers added the Soprano ICE ™ platform to its product portfolio. The Soprano ICE Multi-Platform combines the high absorption benefits of the Alexandrite (755nm) wavelength with the advantages of a diode laser providing more comfort for the patient during hair removal and lower mainten
- Almirall Announces Scientific Research Hub at R&D Centerhttps://practicaldermatology.com/news/almirall-announces-scientific-research-hub-rd-center/2468710/Almirall announced the launch of “The Hive,” a novel scientific research hub located at its R&D center in Barcelona, Spain. According to a press release, the Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s